Document Detail


Progression of left atrial volume index in a population at risk for heart failure: a substudy of the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) trial.
MedLine Citation:
PMID:  22759444     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIMS: Limited data are available concerning the evolution of the left atrial volume index (LAVI) in pre-heart failure (HF) patients. The aim of this study was to investigate clinical characteristics and serological biomarkers in a cohort with risk factors for HF and evidence of serial atrial dilatation. METHODS AND RESULTS: This was a prospective substudy within the framework of the STOP-HF cohort (NCT00921960) involving 518 patients with risk factors for HF electively undergoing serial clinical, echocardiographic, and natriuretic peptide assessment. Mean follow-up time between assessments was 15 ± 6 months. 'Progressors' (n = 39) were defined as those with serial LAVI change ≥3.5 mL/m(2) (and baseline LAVI between 20 and 34 mL/m(2)). This cut-off was derived from a calculated reference change value above the biological, analytical, and observer variability of serial LAVI measurement. Multivariate analysis identified significant baseline clinical associates of LAVI progression as increased age, beta-blocker usage, and left ventricular mass index (all P < 0.05). Serological biomarkers were measured in a randomly selected subcohort of 30 'Progressors' matched to 30 'Non-progressors'. For 'Progressors', relative changes in matrix metalloproteinase 9 (MMP9), tissue inhibitor of metalloproteinase 1 (TIMP1), and the TIMP1/MMP9 ratio, markers of interstitial remodelling, tracked with changes in LAVI over time (all P < 0.05). CONCLUSION: Accelerated LAVI increase was found to occur in up to 14% of all pre-HF patients undergoing serial echocardiograms over a relatively short follow-up period. In a randomly selected subcohort of 'Progressors', changes in LAVI were closely linked with alterations in MMP9, TIMP1, and the ratio of these enzymes, a potential aid in highlighting this at-risk group.
Authors:
Patrick Collier; Chris J Watson; Deidre F Waterhouse; Ian R Dawkins; Anil K Patle; Stephen Horgan; Carmel M Conlon; Rory O'Hanlon; John A Baugh; Mark T Ledwidge; Kenneth McDonald
Related Documents :
8960444 - Treatment for acute myocardial infarction. overview of randomized clinical trials.
9796834 - Mechanism of protective effects of ace inhibition on coronary artery disease.
22381094 - Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic ...
19936114 - Heart rate and cardiovascular disease: an alternative to beta blockers.
3820534 - Rheumatic fever and rheumatic heart disease in japan.
1375674 - Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-3
Journal Detail:
Title:  European journal of heart failure     Volume:  -     ISSN:  1879-0844     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
UCD Conway Institute of Biomolecular and Biomedical Research, Belfield, University College Dublin 4, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multimodal retinal vessel segmentation from spectral-domain optical coherence tomography and fundus ...
Next Document:  Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and prese...